Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.34 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23108676 | 0.85 | ACACB (0.47) | ACACBCHRNB2CHRNA4KCNJ1KCNH2 | |
| SCHEMBL23103979 | 0.82 | HRH4 (0.34) | ACACBCHRNB2CHRNA4HRH4MCHR1 | |
| SCHEMBL23504147 | 0.82 | ACACB (0.33) | ACACB | |
| SCHEMBL23132892 | 0.80 | HRH4 (0.50) | ACACBHRH4 | |
| SCHEMBL25147353 | 0.80 | HRH4 (0.50) | ACACBHRH4 | |
| SCHEMBL23132875 | 0.77 | ACACB (0.43) | ACACBCHRNB2CHRNA4HRH4 | |
| SCHEMBL23133709 | 0.76 | ACACB (0.39) | ACACBCHRNB2CHRNA4KCNJ1KCNH2 | |
| SCHEMBL23114832 | 0.74 | ACACB (0.50) | ACACBCHRNB2CHRNA4KCNJ1KCNH2 | |
| SCHEMBL25146910 | 0.74 | ACACB (0.50) | ACACBCHRNB2CHRNA4KCNJ1KCNH2 | |
| SCHEMBL25147338 | 0.73 | ACACB (0.44) | ACACBCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028085-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11021481-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028085-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists | HIPK1, PDXK, IP6K1 | ACACB 3367/4885CHRNB2 1400/4885CHRNA4 2220/4885 |
| US-11021481-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, PDXK, IP6K1 | ACACB 3367/4885CHRNB2 1400/4885CHRNA4 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.